Vadadustat

Phase 3

Akebia Therapeutics, Inc. (AKBA)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

4mo

AKBAPhase 3$370M

Vadadustat Phase 3 Results Expected

Vadadustat• Anemia350

Jun 15Estimated

CT.gov

00%

Competitive Landscape

1 competitor in Anemia

INCYINCB000928

Phase 2

View Full Landscape

Drug Information

Target Indication

Anemia

Clinical Trial

NCT02680574

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/24/2023

Vafseo

Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AKBA

Akebia Therapeutics, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Erythropoiesis-Stimulating Agent (ESA)Phase 3

Anemia of Chronic Kidney Disease

Mircera®Phase 3

Anemia Associated With Chronic Kidney Disease (CKD)

Darbepoetin alfaPhase 3

Anemia

PraliciguatPhase 2

Focal Segmental Glomerulosclerosis

IW-1973Phase 2

Heart Failure With Preserved Ejection Fraction

View full pipeline